Abstract
A new simple and highly sensitive HPLC-UV method for the analysis of paclitaxel in Taxol® and Abraxane® has been developed which also allows the quantification in biological samples of pharmacokimnetic studies with a very easy sample preparation. The proposed method has advantages over previously reported methods, such as an increase in sensitivity up to 20 times, good accuracy in terms of recovery that allows to work without addition of internal standard and a simple sample preparation in one step.
The analysis was carried out using a Zorbax Eclipse XDB-C18 (4.6 × 150 mm, 3.5 μm) with a column guard. The mobile phase consisted of acetonitrile: water (50: 50) and the flow rate was 1 mL/min, the detection wavelength was 227 nm, the injection volume 5 μL and the analysis was performed at room temperature.
The method was validated according ICH guidelines and FDA guidelines for validation of bioanalytical methods. Linearity was evaluated in the range from 0.005 – 50.0 μg/mL, with a regression coefficient (R2) of 0.9967. LOD and LOQ were 0.001 and 0.005 μg/mL respectively.
Keywords: Paclitaxel, HPLC-UV detection, pharmaceutical formulation, pharmacokinetic studies, validation.
Current Pharmaceutical Analysis
Title:Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples
Volume: 10 Issue: 3
Author(s): Ezequiel Bernabeu, Sabrina Flor, Christian Hocht, Carlos Taira, Diego Chiappetta, Valeria Tripodi and Silvia Lucangioli
Affiliation:
Keywords: Paclitaxel, HPLC-UV detection, pharmaceutical formulation, pharmacokinetic studies, validation.
Abstract: A new simple and highly sensitive HPLC-UV method for the analysis of paclitaxel in Taxol® and Abraxane® has been developed which also allows the quantification in biological samples of pharmacokimnetic studies with a very easy sample preparation. The proposed method has advantages over previously reported methods, such as an increase in sensitivity up to 20 times, good accuracy in terms of recovery that allows to work without addition of internal standard and a simple sample preparation in one step.
The analysis was carried out using a Zorbax Eclipse XDB-C18 (4.6 × 150 mm, 3.5 μm) with a column guard. The mobile phase consisted of acetonitrile: water (50: 50) and the flow rate was 1 mL/min, the detection wavelength was 227 nm, the injection volume 5 μL and the analysis was performed at room temperature.
The method was validated according ICH guidelines and FDA guidelines for validation of bioanalytical methods. Linearity was evaluated in the range from 0.005 – 50.0 μg/mL, with a regression coefficient (R2) of 0.9967. LOD and LOQ were 0.001 and 0.005 μg/mL respectively.
Export Options
About this article
Cite this article as:
Bernabeu Ezequiel, Flor Sabrina, Hocht Christian, Taira Carlos, Chiappetta Diego, Tripodi Valeria and Lucangioli Silvia, Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples, Current Pharmaceutical Analysis 2014; 10(3) . https://dx.doi.org/10.2174/1573412910666140409002944
DOI https://dx.doi.org/10.2174/1573412910666140409002944 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Synergistic Activities of a Silver(I) Glutamic Acid Complex and Reactive Oxygen Species (ROS): A Novel Antimicrobial and Chemotherapeutic Agent
Current Medicinal Chemistry Synergistic Effect of Curcumin: A Review
Current Bioactive Compounds In Vitro Anticancer Evaluation of Platinum(II/IV) Complexes with Diisoamyl Ester of (S,S)-ethylenediamine-N,N’-di-2-propanoic Acid
Anti-Cancer Agents in Medicinal Chemistry Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-κB Inhibitor DHMEQ
Current Pharmaceutical Design PREFACE
Anti-Cancer Agents in Medicinal Chemistry Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface
Current Signal Transduction Therapy Design and Synthesis of Some Newer Pyrimidine Hydroxamates as Histone Deacetylase Inhibitors
Current Enzyme Inhibition Clinical Pharmacogenetics in Oncology: the Paradigm of Molecular Targeted Therapies
Current Pharmaceutical Design Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design Highlights in Peptide Nanoparticle Carriers Intended to Oral Diseases
Current Topics in Medicinal Chemistry Molecular Targeted Agents Combined with Chemo-Radiation in the Treatment of Locally Advanced Cervix Cancer
Reviews on Recent Clinical Trials Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism